Table 3.
Experimental design and results from EBOV mock clinical trial
| PFU/ml (LOD) | n | Avg EBOV reads | Avg %reads mapped | CoV | Positive samples | Negative samples |
|---|---|---|---|---|---|---|
| 1,000,000 (10×) | 16 | 5442.5 | 2.66% | 136.55% | 15 | 1 |
| 500,000 (5×) | 16 | 2777.5 | 2.49% | 152.33% | 13 | 3 |
| 100,000 (1×) | 16 | 351.5 | 0.58% | 247.57% | 9 | 7 |
| NTC | 100 | 4 | 0.00% | 571.69% | 1 | 99 |
Study design and demonstration of the preliminary diagnostic performance of an EBOV MIPS diagnostic assay. This table shows results from a mock clinical trial using 48 Zaire ebolavirus Makona positive samples at three different concentrations (10 × , 5×, and 1 × ) and 100 Ebola negative samples